• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Impax Labs' Parkinson's drug aces late-stage clinical trial

Impax Labs' Parkinson's drug aces late-stage clinical trial

March 18, 2011
CenterWatch Staff

Hayward, Calif.-based Impax Laboratories said the Parkinson's drug it in-licensed from GlaxoSmithKline last year—its second attempt at an extended-release version of caribidopa-levadopa—beat out the standard of care for controlling a key symptom of the disease in a late-stage study, according to FiercePharma.

The primary endpoint of the IPX066 trial was the percentage of "off time"—when patients' medication effect has worn off and there is a return of Parkinson's symptoms—during waking hours. IPX066 demonstrated a 37% improvement from baseline compared to a 17% improvement from baseline for the standard treatment.

"With the successful completion of this ADVANCE-PD trial and the APEX-PD trial in patients with early PD, we have completed the two required phase III trials for a New Drug Application as agreed with the FDA. We are working diligently to file an NDA in the fourth quarter of 2011," said Impax CSO Dr. Suneel Gupta.

Just three months ago GlaxoSmithKline signed a $186 million licensing deal for the program, gaining ex-U.S. rights with an $11.5 million upfront payment and a promise of $175 million in milestones.

The FDA rejected a similar product from Impax, Vadova, in early 2008. A few months later the company announced plans to launch a new development program to create a next-generation carbidopa-levodopa therapy that could leverage the experience it had gained trying to get an approval for Vadova.

    Upcoming Events

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing